StrongBox Wealth LLC Has $1.96 Million Holdings in Kenvue Inc. $KVUE

StrongBox Wealth LLC grew its stake in Kenvue Inc. (NYSE:KVUE) by 8.0% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 93,497 shares of the company’s stock after buying an additional 6,918 shares during the quarter. StrongBox Wealth LLC’s holdings in Kenvue were worth $1,957,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Evergreen Wealth Solutions LLC boosted its holdings in shares of Kenvue by 2.6% in the first quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock valued at $402,000 after buying an additional 432 shares during the period. Fulton Bank N.A. boosted its holdings in shares of Kenvue by 0.6% in the first quarter. Fulton Bank N.A. now owns 78,888 shares of the company’s stock valued at $1,892,000 after buying an additional 465 shares during the period. Scott & Selber Inc. boosted its holdings in shares of Kenvue by 0.4% in the first quarter. Scott & Selber Inc. now owns 106,621 shares of the company’s stock valued at $2,557,000 after buying an additional 475 shares during the period. Wealth Alliance LLC boosted its holdings in shares of Kenvue by 1.6% in the first quarter. Wealth Alliance LLC now owns 31,778 shares of the company’s stock valued at $762,000 after buying an additional 486 shares during the period. Finally, Everett Harris & Co. CA boosted its holdings in shares of Kenvue by 1.4% in the first quarter. Everett Harris & Co. CA now owns 36,971 shares of the company’s stock valued at $887,000 after buying an additional 500 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE KVUE opened at $18.07 on Wednesday. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The firm’s fifty day moving average price is $21.04 and its two-hundred day moving average price is $22.16. Kenvue Inc. has a 1 year low of $17.15 and a 1 year high of $25.17. The firm has a market capitalization of $34.68 billion, a P/E ratio of 24.42, a price-to-earnings-growth ratio of 2.62 and a beta of 0.83.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same period in the prior year, the firm posted $0.32 earnings per share. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.6%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s payout ratio is currently 112.16%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on KVUE shares. JPMorgan Chase & Co. reduced their price target on shares of Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a report on Friday, July 25th. Royal Bank Of Canada cut their price objective on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research report on Friday, August 8th. Bank of America cut their price objective on shares of Kenvue from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, July 15th. Zacks Research raised shares of Kenvue to a “strong sell” rating in a research report on Monday, August 11th. Finally, Canaccord Genuity Group cut their price objective on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $24.04.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.